FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry, specifically to a composition for treating cancer, comprising (a) cabazitaxel and (b) sulfobutyl ether beta cyclodextrin, and the composition does not contain ethanol. Preferably, the weight ratio of (a) to (b) ranges from 1:30 to 1:1,000.
EFFECT: invention ensures stability of the composition in an aqueous medium, which allows administration of therapeutic doses of the drug without the need for ethanol and surfactants.
10 cl, 9 ex, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF BENDAMUSTINE AND CYCLOPOLYSACCHARIDE | 2010 |
|
RU2591804C2 |
| BENDAMUSTINE AND CYCLOPOLISACCHARIDE COMPOSITION | 2011 |
|
RU2647368C2 |
| COMPOSITIONS CONTAINING POLYSACCHARIDE MATRIX FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS | 2017 |
|
RU2748261C2 |
| BENDAMUSTINE AND CYCLOPOLYSACCHARIDE COMPOSITIONS | 2010 |
|
RU2734236C2 |
| LYOPHILISED PREPARATION OF CYTOTOXIC DIPEPTIDES | 2012 |
|
RU2597154C2 |
| COMPOUND ON BASIS OF ARIPIPRAZOLE COMPLEX | 2003 |
|
RU2342931C2 |
| STABILISED PHARMACEUTICAL DOCETAXEL-CONTAINING COMPOSITION | 2009 |
|
RU2478370C2 |
| FORMULATIONS OF 2-IMINOBIOTINE AND USE THEREOF | 2011 |
|
RU2627460C2 |
| COMPOSITIONS WHICH CONTAIN EPOTHILONE, AND METHOD OF THEIR OBTAINING | 2005 |
|
RU2416407C2 |
| COMPOSITION OF BCL-2 INHIBITOR BASED ON CYCLODEXTRIN | 2019 |
|
RU2804366C2 |
